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Nonalcoholic fatty liver disease (NAFLD) and diabetes are common metabolic disorders whose prevalence rates are expected to 
rise worldwide, corresponding to aging and increasingly obese populations. Compared to the general population (around 25%), 
50% to 70% of people with diabetes have NAFLD, and NAFLD severity (including fibrosis) tends to be worsened by the presence of 
diabetes. NAFLD is considered an emerging risk factor for type 2 diabetes mellitus and a contributor to the development of chronic 
diabetes-related complications. This reciprocal relationship demonstrates the importance of confirming suspected NAFLD in pa-
tients with diabetes. Due to the invasive nature of liver biopsy to assess NAFLD status, various alternative non-invasive modalities 
have been developed and validated. Here, we summarized the epidemiology of NAFLD in patients with diabetes and reviewed cur-
rently available imaging modalities and biomarker-based prediction models for their ability to detect liver steatosis and/or fibrosis.
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INTRODUCTION
The prevalence of diabetes is rising. According to Diabetes At-
las 2017, 425 million people suffer from diabetes worldwide; 
the prevalence rate in Korea is 14.4% according to the Diabetes 
Fact Sheet 2018 [1,2]. Type 2 diabetes mellitus (T2DM) is 
caused by derangements in multiple organs and by various 
pathophysiological abnormalities, such that it is implicated in 
many other diseases related to insulin resistance and obesity, 
such as nonalcoholic fatty liver disease (NAFLD), sleep apnea, 
arthritis, cardiovascular disease (CVD), and metabolic syn-
drome (MetS) [3,4].
NAFLD is considered the hepatic manifestation of ectopic 
fat accumulation caused by abdominal obesity and insulin re-
sistance; its presence also reflects visceral, intramuscular, epi-
cardial, and perivascular fat accumulation. Recent evidence 
suggests that NAFLD should be considered a cardiovascular 
risk factor [4]. NAFLD is a strong clinical signal for insulin re-
sistance and MetS, and is considered a confirmative risk factor 
for T2DM [2]. Prevalence of NAFLD in patients with T2DM is 
much higher than in the general population. This review sum-
marizes the epidemiology of NAFLD relative to T2DM, and 
compares various approaches to diagnose and assess NAFLD 
characteristics, including steatohepatitis and fibrosis.
PREVALENCE OF NAFLD IN THE GENERAL 
POPULATION
The current prevalence of NAFLD is proportional to increased 
rates of obesity. NAFLD incidence in the general population is 
about 25%, but it rises to more than 90% for very obese indi-
viduals undergoing weight reduction procedures/surgeries [5]. 
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In addition, like obesity, NAFLD displays different characteris-
tics among various ethnic groups and across countries [6].
In the general Korean population, some discrepancies exist 
in NAFLD prevalence. In a study by Park et al. [7] in which 
4,967 young, healthy Koreans participated in a health screen-
ing program, the age-adjusted NAFLD prevalence rate was 
21.6% (men), 11.2% (women), and 16.1% in the whole popula-
tion. According to Jeong et al. [8], in a cross-sectional study of 
140,000 participants in a health screening program, the 
NAFLD prevalence rate was 25.2%, with some differences 
based on where participants lived.
 
PREVALENCE OF NAFLD IN PATIENTS WITH 
T2DM 
NAFLD prevalence in patients with T2DM is much higher 
than in the general population. In a systemic review by Lonar-
do et al. [9], the NAFLD incidence rate in patients with T2DM 
is 50% to 75%, according to ethnicity, across studies. In reverse, 
the prevalence of diabetes in patients with NAFLD is higher 
than in the general population. In a study by Browning et al. 
[10] of 2,287 urban people participating in the Dallas Heart 
Study, hepatic triglyceride content was measured by 1H-nucle-
ar magnetic resonance spectroscopy (MRS), with prevalence 
of T2DM or impaired fasting glucose (IFG) reported as 18% to 
33% in patients with NAFLD. 
There is discrepancy between the studies regarding preva-
lence of NAFLD in patients with T2DM, which may be ac-
counted for by the diagnostic tools used [11]. The prevalence 
of NAFLD was 20.3% when plasma alanine aminotransferase 
was used to define NAFLD, whereas the prevalence reached 
72.8% when MRS was used to define NAFLD. In addition, 
NAFLD prevalence in patients with T2DM significantly in-
creased with increasing obesity [11]. 
NAFLD prevalence in Asians is never lower than in Cauca-
sians. In 929 Korean patients with T2DM who visited a univer-
sity-based diabetes clinic, NAFLD was assessed by ultrasono-
gram [12], and 63.3% of patients had NAFLD. In 8,352 Japa-
nese patients who received health check-ups from 2009 to 
2010, NAFLD incidence was 25.6% in those with normal fast-
ing glucose, 56.2% in those with IFG, and 68% in those with 
T2DM defined as fasting blood glucose ≥126 mg/dL, suggest-
ing NAFLD prevalence could differ by glycemic status [13].
NAFLD AS A RISK FACTOR FOR T2DM 
There is convincing evidence that NAFLD often precedes the 
development of T2DM [14]. Some suggest that the convention-
al paradigm of NAFLD to represent ‘hepatic manifestation’ of 
MetS is outdated, as recently NALFD has been shown to be an 
early predictor and determinant for development of diabetes. 
By examining the pathophysiological aspects of insulin resis-
tance in NAFLD development, we can understand the intimate 
relationship between these conditions. NAFLD is associated 
with hepatic and peripheral insulin resistance, causing insuffi-
cient suppression of hepatic gluconeogenesis, decreased glyco-
gen synthesis, and increased lipid accumulation [3]. The influx 
of high amounts of free fatty acid (FFA) from white adipose and 
dietary lipids into the liver promotes further glucose synthesis. 
De novo synthesis of FFA is driven by sterol regulatory element 
binding-protein 1c (Srebp-1c) and carbohydrate response ele-
ment binding-protein (ChREBP), catalyzed by hyperinsu-
linemia and hyperglycemia. Further factors such as decreased 
lipid export through very-low density lipoprotein, increased he-
patic insulin resistance via diacylglycerol, and increased oxida-
tive stress mediated due to exhaustion of antioxidant capacities 
of superoxide dismutase and glutamate peroxidase, ultimately 
result in development of NAFLD and progression to nonalco-
holic steatohepatitis (NASH) in insulin resistant patients.
Meta-analyses have shown a 1.6- to 6.8-fold increased risk for 
diabetes in subjects with NAFLD according to established diag-
nostic methods, definitions, and the risk factors included for 
adjustment in the model [4,15]. In 5,372 non-diabetic Koreans 
in whom health screening was performed repeatedly in 5 years; 
interval, after adjustment for confounding factors, relative risk 
for T2DM was 1.97 in all participants and 2.29 after excluding 
frequent drinkers [16]. In another study analyzed in nondiabet-
ic 11,091 Koreans in whom health screening was performed re-
peatedly in 5 years; interval, the odds ratio for T2DM was 2.05 
after adjustment for confounding factors, and this risk was 
highest in those with the highest baseline insulin levels [17]. 
Although NAFLD is a definite risk factor for T2DM, risk 
could be attenuated if NAFLD is resolved. In 13,218 nondiabet-
ic Korean participants in a health promotion center, incident 
diabetes was assessed at 5 years [18] by dividing them into six 
groups according to hepatic steatosis status at baseline and 5 
years later. Using “no steatosis at baseline or follow-up” as the 
reference group, steatosis at baseline and follow-up showed a 
2.78-fold increased risk for T2DM, and worsening severity of 
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steatosis at follow-up showed a 7.38-fold increased risk. How-
ever, steatosis at baseline but not at follow-up showed no in-
creased risk for T2DM compared to the reference group, sug-
gesting that resolution of steatosis attenuated T2DM risk. Simi-
lar results were observed in another study of 4,604 Japanese 
participants at 10 years of follow-up [19]. In a study by Bae et al. 
[20], NAFLD status was assessed in 7,849 non-diabetic subjects 
over 5 years. Those with NAFLD for 5 consecutive years showed 
a 1.55-fold increased risk for T2DM compared with those who 
never had NAFLD, and participants with intermittent NAFLD 
showed no increased risk for T2DM, suggesting that persistent 
NAFLD presence affects risk for T2DM more strongly.
While it is evident that NAFLD is a significant risk factor for 
T2DM, certain conditions promote that risk. In a retrospective 
study of 12,853 non-diabetic Korean participants, those with 
any of insulin resistance, overweight/obesity, and steatosis in-
dependently doubled the risk of T2DM [21]. However, when 
these three conditions co-occurred, risk increased 14-fold, 
suggesting their combined influence on T2DM risk. In a study 
by Bae et al. [22], participants with IFG and NAFLD showed a 
9-fold increased risk for T2DM at 5 years compared with the 
group without IFG and NAFLD. In addition, there was an ad-
ditive effect of NAFLD on development of T2DM in individu-
als with MetS, and the risk for T2DM increased when elevated 
liver enzymes or increased fibrosis scores were accompanied 
by NAFLD [23-25]. 
It is apparent that NAFLD is an established risk factor for 
T2DM. Further, NAFLD resolution attenuates T2DM risk, but 
when obesity, insulin resistance, or hyperglycemia is combined 
with NAFLD, T2DM risk significantly increases.
T2DM AS A RISK FACTOR FOR NASH AND 
FIBROSIS
While presence of NAFLD may not predict any clinical abnor-
malities other than T2DM, progression of NAFLD to NASH or 
fibrosis, and further development of cirrhosis, is a serious 
problem. A 10% to 35% of those with normal liver histology 
progresses to steatosis and 12% to 40% of those with hepatic 
steatosis progress to steatohepatitis, and up to 15% of patients 
with NASH are known to progress to cirrhosis [26].
The factors that affect progression of NAFLD to NASH are 
unknown. One study reports on 129 biopsy-proven subjects 
with NAFLD that were followed for 13.7 years [27]. Although 
baseline glycemic status was unknown, 78% of participants at 
follow-up had diabetes, and insulin resistance was more prom-
inent in those with progressive versus nonprogressive fibrosis, 
suggesting dysglycemia as a factor for progression to fibrosis. 
In 1,918 Hong Kong patients with diabetes in whom fibroscan 
was performed, 17.7% showed significant liver stiffness [28]. 
In a Rotterdam study of 3,041 participants, those with baseline 
diabetes and NAFLD showed a significantly higher probability 
of liver stiffness compared as those without diabetes or 
NAFLD, and age, diabetes and NAFLD were the factors that 
aggravated liver stiffness [28,29]. In 108 patients who had two 
liver biopsies in a median interval of 6.6 years, there was a sig-
nificantly higher proportion of patients with T2DM among 
those who progressed to fibrosis compared with those who did 
not [30]. In one study of biopsy-proven NAFLD patients, the 
proportion of those with diabetes significantly increased as fi-
brosis stage worsened from 0 to 4 [31]; and in another study, 
diabetes was the significant predictor for fibrosis in patients 
with biopsy-proven NAFLD [32]. 
Based on these results, Tilg et al. [3] recently suggested a 
clinical algorithm to screen and manage NAFLD by which pa-
tients with NAFLD should be screened for MetS and T2DM 
and, as patients with T2DM are at very high risk for NAFLD, 
screening for NAFLD should be performed irrespective of se-
rum liver enzyme levels and elastography should be consid-
ered in these patients to detect liver stiffness. 
NAFLD AS AN AGGRAVATING FACTOR FOR 
DIABETIC COMPLICATIONS
There is evidence that presence of NAFLD in patients with 
T2DM aggravates diabetic complications [33]. In 2,839 T2DM 
patients, those with NAFLD showed a significantly higher 
prevalence of CVD [34]. The risk for macrovascular complica-
tions remained significantly increased after adjustment for 
multiple risk factors. In 2,103 patients with T2DM and 
NAFLD ascertained by history and ultrasonogram, the risk for 
proliferative retinopathy and chronic kidney disease, respec-
tively, were 1.75- and 1.87-fold increased compared with those 
who did not have NAFLD, suggesting risk for microvascular as 
well as macrovascular complications is significantly associated 
with NAFLD in T2DM [35]. 
Other study results suggest increased mortality in patients 
with T2DM and NAFLD. In 337 patients with diabetes fol-
lowed for 10.9 years, more liver-related deaths occurred in 
those with versus without NAFLD [36]. In addition, in a mul-
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tivariate model, NAFLD significantly predicted death in pa-
tients with T2DM after adjustment for confounding factors. 
Increased risk for diabetic complications in the presence of 
NAFLD was similarly observed in patients with type 1 diabetes 
mellitus (T1DM). In 250 T1DM patients, NAFLD prevalence 
was 44.4%, and the prevalence of CVD and microvascular dis-
ease was significantly higher in those with versus without 
NAFLD [37,38]. These results suggest a deleterious effect of 
NAFLD on vasculature, which is commonly seen in patients 
with T1DM and T2DM.
DIAGNOSIS OF NAFLD 
In individuals with and without diabetes, a two-step process 
should be used to diagnose NAFLD: (1) existence of hepatic 
steatosis, either by imaging or histology; and (2) exclusion of 
secondary causes of liver steatosis as described in Table 1 
[39,40]. Other endocrinologic disorders such as hypothyroid-
ism, hypopituitarism, and hypogonadism are also associated 
with NAFLD; therefore, related laboratory assessments should 
be considered for patients with signs or symptoms of these en-
docrinopathies.
NAFLD spans the spectrum of fatty liver conditions, from 
simple steatosis (nonalcoholic fatty liver [NAFL]) and steato-
hepatitis (NASH) to advanced fibrosis or cirrhosis. By histo-
logic liver biopsy, NAFL is defined as ≥5% hepatic steatosis 
with no evidence of hepatocellular injury (hepatocyte balloon-
ing). NASH is a combination of NAFL and inflammation with 
hepatocyte injury (e.g., ballooning), with or without fibrosis. 
IMAGING MODALITIES TO ASSESS HEPATIC 
STEATOSIS
Despite its invasive nature and sampling variability [41], liver 
biopsy remains the gold standard to assess hepatic steatosis, 
inflammation, and fibrosis in patients with NAFLD. It should 
be considered for patients suspected to have advanced fibrosis 
or when exclusion of other chronic liver diseases is needed. To 
overcome its high costs and risks, alternative noninvasive im-
aging, clinical, and laboratory modalities have been developed 
and validated to diagnose NAFLD.
Currently, ultrasonography (US), computed tomography 
(CT), magnetic resonance imaging (MRI), MRS, and transient 
elastography (TE) are widely available tools to measure hepatic 
steatosis (Table 2) [42-51]. 
Ultrasonography
US is the recommended first line screening method for pa-
tients with T2DM by the European NAFLD guidelines [42]. 
Although US has interobserver variability and limited sensitiv-
ity to detect mild (<20%) steatosis [52] or morbid obesity 
(body mass index [BMI] >40 kg/m2) [53], it can provide addi-
tional information about liver structure. In a meta-analysis, US 
achieved pooled sensitivity of 84.8% and pooled specificity of 
93.6% to detect ≥20% to 30% steatosis, compared with histol-
ogy [52]. However, US is limited in accuracy and reproducibil-
ity as echogenicity, an essential sonographic feature to assess 
degree of fat content, can be affected by various patient (obesi-
ty, coexistent kidney disease) and acquisition (device, operator, 
instrument settings) factors. 
Computed tomography
CT scanners are standardized to obtain pixel value measure-
ments relative to water using a dimensionless unit known as 
the Hounsfield unit (HU). Radiodensity of water is 0 HU by 
definition and air is defined as −1,000 HU [54]. In non-con-
trast CT, normal liver parenchyma and fat are about 50 to 60 
and −20 to −100 HU, respectively. Due to inconsistency in HU 
Table 1. Secondary causes of hepatic fat accumulation
Categories Description
Alcohol Intake, weekly: >140 g or 14 standard drinks (women), >210 g or 21 standard drinks (men) 
Viral hepatitis Serological evidence for hepatitis B or hepatitis C virus infection
Steatogenic drugs Exposure history of valproic acid, tamoxifen, aromatase inhibitors, corticosteroids, tetracycline, amiodarone, 
methotrexate, mipomersen, lomitapide, etc.
Autoimmune disorder Autoimmune hepatitis, celiac disease
Hereditary liver diseases Hemochromatosis, Wilson’s disease, α1-antitrypsin deficiency, lipodystrophy
Others Hypobetalipoproteinaemia, surgically altered bowel anatomy, pancreatoduodenal resection, etc.
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calibration by external factors, ‘fat-free spleen’ can be used as 
an internal reference [55]. Although various criteria to define 
steatosis have been proposed, hepatic HU less than 40 or (liver 
HU−spleen HU) less than −10 can detect steatosis [43] with 
sensitivity and specificity ranging from 46% to 72% and 88% 
to 95%, respectively [56]. Similar to US, CT has limited sensi-
tivity to detect mild steatosis (<30% liver fat). Radiation expo-
sure is an additional drawback. Although CT can quantitative-
ly measure hepatic steatosis, it is an unfavorable modality to 
diagnose fatty liver in the clinical setting. A few clinical trials of 
patients with T2DM applied CT scan to monitor changes in 
hepatic steatosis [57,58]. 
Magnetic resonance imaging
To date, MRI showed the most powerful performance for as-
sessing steatosis. MRI-based methods are generally divided 
into two classes: MRS and MRI-proton density fat fraction 
(MRI-PDFF). MRS is considered the gold standard for quanti-
fication of hepatic triglyceride (fat) content [42,44], as it is sen-
sitive enough to detect trace amounts of liver fat. MRS is more 
a biochemical-based technique than imaging. It quantifies the 
signal intensity of proton at frequencies corresponding to wa-
ter or fat within the voxel-of-interest, and the fat signal fraction 
is calculated. In a recent meta-analysis with histology as the 
reference, MRS showed high diagnostic accuracy to detect 
mild steatosis (histological grade ≥5%) with sensitivity and 
specificity of 89% and 84%, respectively [59]. However, major 
limitations of MRS are: high cost; time consumption; need for 
specialized expertise and devices; and small volume of mea-
surements (usually <3×3×3 cm in size), which may cause 
Table 2. Summary of currently used imaging devices for quantification of hepatic steatosis and fibrosis
Device Detection criteria
Accuracy 
reproducibility 
quantification
Hepatic 
volume of 
assessment
Time 
accessibility Cost Specific comments
Hepatic steatosis
   US Specific sonographic 
findings [51]
+ +++ +
(bedside)
+ Cannot detect mild steatosis, Observer 
dependency
   CT liver HU <40 or liver 
HU−spleen HU <−10 
[43]
++ +++ ++ ++ Radiation hazard
Diverse criteria for definition (liver/
spleen ratio of HU, etc.)
Low sensitivity in mild steatosis
   MRI-PDFF ≥5.6% liver fat [42,44] +++ +++ +++ +++ Optimal for clinical trials
   MRS +++ + +++ +++ Gold standard
Sampling errors
Require expertise/device
   CAP by TE CAP ≥248 dB/m [46] 
or ≥288 dB/m [47]
++ + +
(bedside)
+ Not linear in higher liver fat content
Results are affected by BMI, diabetes, 
etiology
XL probe for the obese
Hepatic fibrosis
   MRE Advanced fibrosis (F3) 
threshold >2.4–5.55 
kPa [45]
+++ +++ +++ +++ Diverse cut-points by types of modality 
(2D, 3D, etc.)
Most accurate but expensive
Failure risk in iron overload condition
   LSM by TE Diverse cut-points 
(7.3– 9.9 kPa) for ad-
vanced fibrosis (F3) 
[48-50]
++ + +
(bedside)
+ Affected by BMI (failure risk)
XL probe for the obese
TE can measure CAP and LSM simul-
taneously 
US, ultrasonography; CT, computed tomography; HU, Hounsfield unit; MRI-PDFF, magnetic resonance imaging proton density fat fraction; 
MRS, magnetic resonance spectroscopy; CAP, controlled attenuation parameter; TE, transient elastography; BMI, body mass index; MRE, mag-
netic resonance elastography; kPa, kilopascals; LSM, liver stiffness measurement; 2D, two dimensional; 3D, three dimensional; CAP, controlled 
attenuation parameter. 
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sampling errors. 
Several MRI-based methods have been developed for mea-
suring liver fat content. MRI-PDFF is a fundamental tissue 
trait and can be calculated as the (proton signal from magnetic 
resonance [MR]-visible triglyceride)/(total proton signal in-
cluding triglyceride and water) [54,60]. Therefore, internal cal-
ibration or a reference standard is not needed. The diagnostic 
accuracy of MRI-PDFF to detect steatosis is comparable to 
MRS or liver biopsy [45,54,61], while it also allows whole im-
aging of the liver where fat is measured. This can minimize 
sampling error, making MRI-PDFF useful for monitoring pa-
tients sequentially, such as in NAFLD clinical trials [45,62,63]. 
Transient elastography
Controlled attenuation parameter (CAP) is a simple quantita-
tive index based on the properties of ultrasonic signals exam-
ined by transient liver elastography (Fibroscan; Echosens, Par-
is, France). Based on the concept that fat attenuates US propa-
gation, it quantifies US attenuation at the center frequency of 
the Fibroscan M probe (3.5 MHz) or XL probe (2.5 MHz) 
within approximately 3 cm3 of liver volume [64]. Recent meta-
analysis with CAP measurements in patients with various 
chronic liver diseases including NAFLD (20% of the total pop-
ulation), demonstrated its diagnostic accuracy to detect hepat-
ic steatosis with sensitivity and specificity of 69% and 82%, re-
spectively (area under the receiver operating characteristic 
curve [AUROC]=0.823) [46]. Optimal cut-off values for de-
fining S1, S2, and S3 were 248, 268, and 280 dB/m, respectively. 
The authors proposed that individual CAP values should be 
interpreted after adjustment for presence of diabetes, steatosis 
etiology (NAFLD), and BMI, as these factors can overrate CAP 
values [46]. Wong et al. [65] recently established validity crite-
ria for CAP measurement by M probe in clinical practice. In-
terquartile range (IQR), which can be derived from 10 repeat-
ed values of CAP, reflects the fluctuation of CAP measure-
ments. If IQR >40 dB/m, accuracy of CAP to diagnose steato-
sis substantially declines. Caussy et al. [47] proposed a cut-off 
value of 288 dB/m for CAP measurement of hepatic steatosis 
(defined as MRI-PDFF ≥5%), with improved diagnostic accu-
racy when the IQR was <30 dB/m. The discrepancy in CAP 
cut-points in the two previous studies may be due to differenc-
es in obesity prevalence, NAFLD, and diabetes. To reduce the 
failure rate of CAP measurements in obese (BMI ≥30 kg/m2) 
patients, XL probe is recommended [66,67]. In biopsy-proven 
NAFLD patients, MRI-PDFF was more accurate than CAP in 
diagnosing all grades of steatosis [48,68]. Notably, CAP 
showed a non-linear relationship with liver fat content in pa-
tients with severe fatty liver, indicating a limitation to discrimi-
nate moderate and severe steatosis (grade 2 vs. 3). Lee et al. 
[69] recently conducted an efficacy study of NAFLD using 
CAP as a primary endpoint in T2DM patients, to assess its 
utility in clinical trials.
Compared to MRI-PDFF, TE-based CAP showed relatively 
lower accuracy to detect steatosis whereas its advantages in-
clude cost and accessibility. More research on these modalities, 
to evaluate and define their distinct roles, are warranted [70].
IMAGING MODALITIES TO ASSESS NASH 
AND HEPATIC FIBROSIS
To date, no imaging technique can reliably diagnose NASH. In 
contrast, liver fibrosis can be indirectly quantified by measur-
ing liver stiffness using imaging modalities such as magnetic 
resonance elastography (MRE) and TE, because fibrotic liver 
contains a high level of collagen resulting in tissue rigidity. 
Magnetic resonance elastography 
MRE uses vibration to generate low frequency mechanical 
waves in liver tissue, visualize the propagating waves using a 
phase contrast MRI technique, and then transform the wave 
information into quantitative images reflecting liver stiffness 
[71]. Contrary to the European NAFLD guidelines, United 
States guidelines state that MRE is useful to identify advanced 
fibrosis in patients with NAFLD [40] due to its better perfor-
mance in discriminating stage 1 and ≥2 fibrosis compared to 
TE [68]; furthermore, MRE’s superiority to detect fibrosis was 
confirmed in a meta-analysis [49]. Although it is reliable, re-
producible, and the most accurate method for estimating he-
patic fibrosis, MRE is expensive, not widely available in many 
clinics, and requires specialized expertise to obtain acceptable 
images. 
Transient elastography
TE (Fibroscan) is a point-of-care imaging technique using US 
in which propagation velocity directly reflects tissue elasticity 
to 1 cm wide and 4 cm long [72]. This can quickly generate a 
surrogate marker of liver fibrosis stage called liver stiffness 
measurement (LSM). Results are described as the median val-
ues of 10 validated measurements, ranging from 2.5 to 75.0 ki-
lopascals (kPa), with healthy liver values <5.5 kPa [73]. Impor-
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tantly, validity criteria of LSM by TE include a success rate (ra-
tio of valid measurements to total measurements) >60% and 
an IQR/median LSM ratio of <0.3 [74]. TE has been intensive-
ly studied in patients with viral hepatitis; however, its diagnos-
tic accuracy for hepatic fibrosis was recently validated in 
NAFLD patients [50,75]. Notably, LSM was more correlated 
with fibrosis stage in individuals with severe fibrosis (F3) and 
cirrhosis (F4) [75,76]. TE has higher negative predictive values 
for excluding advanced fibrosis than positive predictive values 
for detection [75], indicating that additional surrogate markers 
for fibrosis can enhance the ability to diagnose advanced fibro-
sis or cirrhosis. A major weakness of TE is a high failure risk in 
obese patients [77] and low accuracy to detect fibrosis in high 
BMI patients [75]. As T2DM patients tend to be obese, this is-
sue should be carefully considered before utilizing TE. In such 
cases, XL-probe may provide more reliable results for morbidly 
obese patients [78]. Due to its accessibility, low cost, and mod-
erate accuracy, TE is recommended by both United States and 
European NAFLD guidelines as an acceptable non-invasive 
method to identify patients at low risk of advanced fibrosis/cir-
rhosis [40,42].
BIOMARKER-BASED PREDICTION MODELS 
TO ASSESS STEATOSIS, NASH, AND HEPATIC 
FIBROSIS
Besides imaging modalities, several noninvasive biomarker 
models have been developed to predict NASH and fibrosis. As 
NAFLD patients with diabetes are at high risk for NASH and 
fibrosis, which are significantly associated with morbidity and 
mortality, evaluation of these conditions is essential for clinical 
management [42]. Models incorporating both clinical and lab-
oratory parameters, which are directly or indirectly linked to 
liver status, provide enhanced diagnostic accuracy to identify 
high risk individuals [79]. 
Hepatic steatosis
Many noninvasive prediction models have been proposed to 
detect hepatic steatosis in NAFLD cohorts (Table 3) [80-87]. 
The majority of models are derived from datasets with fatty 
liver defined by US. European NAFLD guidelines state that 
fatty liver index (FLI), SteatoTest (BioPredictive, Paris, France), 
and NAFLD liver fat score are well-validated models to detect 
steatosis in the general population [42]. FLI, NAFLD liver fat 
score, hepatic steatosis index (HSI), and comprehensive/sim-
ple NAFLD scores (CNS/SNS) were externally validated in the 
Korean population. Depending on population characteristics, 
cut-off values of these models might be adjusted to improve 
sensitivity and specificity [80]. Epidemiologic studies with no 
imaging information can apply these models to calculate an 
operational definition for hepatic steatosis [88], but prudent 
interpretation/application of multiple models is needed. How-
ever, these biomarker-based indices do not add much diagnos-
tic information for clinicians who routinely perform imaging 
studies such as US for patients with suspected NAFLD. 
NASH
Currently there are no well-established prediction models or 
biomarkers to distinguish NASH from steatosis, despite inten-
sive efforts [42]. Circulating levels of cytokeratin-18 (CK-18) 
fragments, which are released from apoptotic or dead cells, 
have been extensively investigated as a novel biomarker [89]; 
however, its clinical utility remains unknown due to low repro-
ducibility and measurement issues [90]. Other panels com-
bined with novel biomarkers, such as NASH test (BioPredic-
tive) [91], NASH diagnostics [92], and OxNASH score [93] 
have been introduced. Further research is required to validate 
their accuracy and practical utility. 
Hepatic fibrosis
Severity of hepatic fibrosis is the most powerful determinant of 
long-term outcomes, including mortality [94,95]; thus, nonin-
vasive assessment of fibrosis is essential to manage patients 
with NAFLD. Beyond imaging modalities to estimate hepatic 
fibrosis, several prediction scores have been developed and 
validated to identify or exclude advanced fibrosis. Focusing on 
reliable blood-based predictive models in the NAFLD guide-
lines, equations, cut-points for advanced fibrosis (F3), infor-
mation about the original development cohort, and external 
validation in individuals with NAFLD are summarized in Ta-
ble 4 [96-104]. This review does not compare diagnostic perfor-
mance of these models due to limited space. 
Contrary to steatosis or NASH scores, fibrosis prediction 
models in clinical practice are recommended in the recent 
NAFLD guidelines [40,42] because some models have achieved 
acceptable accuracy to detect significant fibrosis and have been 
widely validated in NAFLD patients. The NAFLD fibrosis 
score (NFS) [96] and fibrosis-4 (FIB-4) index [97] are current-
ly the most studied decision-making systems and are clinically 
endorsed by both European and United States NAFLD guide-
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lines. The National Institute for Health and Care Excellence 
(NICE, London, United Kingdom) recommended use of the 
Enhanced Liver Fibrosis (ELF) panel, a commercial diagnostic 
kit using fibrosis-related biomarkers, for NAFLD manage-
ment. These blood-based fibrosis prediction models perform 
better when excluding advanced fibrosis versus diagnosing it, 
due to higher negative predictive values [105]. Therefore, com-
bining results from both imaging modalities and biomarker-
based scores may be a better approach to identify ambiguous 
patients at risk for advanced fibrosis or who need liver biopsy. 
Table 3. Summary of biomarker-based prediction models to assess hepatic steatosis
Indices Equations Cut-points Development cohort
External 
validation
FLI (2006) [81] =1/[1+exp (−Y)]×100,
Y=0.953×loge (TG, mg/dL)+0.139×BMI+0.718×loge (GGT, U/L)+0.053×WC− 
15.745
≥60, <30 NAFLD by US 
(Italy)
Yes (validated 
in Korean)
SteatoTest 
(2005) [82]
α2-Macroglobulin, haptoglobin, apolipoprotein A1, total bilirubin, GGT, FPG, 
TG, cholesterol, ALT, age, sex, BMI
NA NAFLD by  
biopsy 
(France)
Yes
NAFLD liver 
fat score 
(2009) [83]
=−2.89+1.18×MetS+0.45×diabetes (yes=2/no=0)+0.15×(fSinsulin, μU/L)+ 
0.04×AST+0.94×AST/ALT
>−0.64 NAFLD by 
MRS  
(Finland)
Yes (validated 
in Korean)
HIS (2010) 
[84]
=8×ALT/AST+BMI (+2, if diabetes; +2, if female) ≥36, <30 NAFLD by US 
(Korean)
Yes (validated 
in Korean)
CNS (2014) 
[80]
=1/[1+exp (−Y)]×100
Y (male)=0.016×age+0.182×BMI+0.089×WC+0.391×alcohol+0.124×exercise 
(yes=0/no=1)+0.018×FPG (mg/dL)+0.773×loge (TG, mg/dL)−0.014× 
HDL-C (mg/dL)+0.145×uric acid (mg/dL)−0.674×loge (AST)+1.632×loge 
(ALT)−21.695
Y (female)=0.320×BMI+0.044×WC+0.533×diabetes+0.016×FPG+0.951×loge 
(TG)−0.015×HDL-C+0.199×uric acid−0.645×loge (AST)+1.302×loge 
(ALT)+0.255×menopause−19.741
≥40 NAFLD by US 
(Korean)
Yes (validated 
in Korean)
SNS (2014) 
[80]
=Points, Age ≥35=1 
WC (male)=80–89/90–99/≥100=2/3/4
WC (female)=75–84/85–94/≥95=1/2/3
BMI (male)=23–24/25–26/≥27=1/2/3
BMI (female)=23–24/25–26/≥27=2/3/4
Diabetes=2
Dyslipidemia=2
No regular exercise=1
Alcohol=1 for male
Menopause=1 for female
≥8 NAFLD by US 
(Korean)
Yes (validated 
in Korean)
ZJU index 
(2015) [85]
=BMI+FPG (mmol/L)+TG (mmol/L)+3×ALT/AST (+2, if female) > 38, <32 NAFLD by US 
(China)
Yes
FSI (2016) [86] =−7.981+0.011×age (years)−0.146×sex (female=1, male=0)+0.173× 
BMI+0.007×TG (mg/dL)+0.593×hypertension+0.789×diabetes+1.1×ALT/
AST ratio ≥1.33 (yes=1, no=0)
≥23 NAFLD by CT 
(USA)
Yes
Chinese 
NAFLD score 
(2016) [87]
=−4.632+0.303×MetS+0.157×T2DM (yes =2, no=0)+0.078×fSinsulin  
(μU/L)+0.168×BMI−0.879×AST/ALT
>−0.79 NAFLD by US 
(China)
Yes 
FLA, fatty liver index; TG, triglyceride; BMI, body mass index; GGT, γ-glutamyltransferase; WC, waist circumference; NAFLD, nonalcoholic 
fatty liver disease; US, ultrasonography; FPG, fasting plasma glucose; ALT, alanine aminotransferase; NA, not available; MetS, metabolic syn-
drome; fSinsulin, fasting serum insulin; AST, aspartate aminotransferase; MRS, magnetic resonance spectroscopy; HSI, hepatic steatosis index; 
CNS, comprehensive NAFLD score; HDL-C, high density lipoprotein cholesterol; SNS, simple NAFLD score; ZJU, Zhejiang University; FSI, 
Framingham Steatosis Index; CT, computed tomography; T2DM, type 2 diabetes mellitus.
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CONCLUSIONS 
Compared to the general population, NAFLD is widely preva-
lent in patients with T2DM, and incidence of both metabolic 
diseases is steadily increasing worldwide. Accumulating evi-
dence indicates that T2DM is considered an emerging risk fac-
tor for NASH and/or fibrosis and that NAFLD may worsen di-
abetes-related health outcomes, such as vascular complica-
tions, and mortality. Extensive assessment of NAFLD severity 
and of cardiometabolic risk profiles is highly recommended for 
management of patients with T2DM. Although many imaging 
modalities and biomarker-based prediction models have been 
developed to evaluate NAFLD disease status, more investiga-
tion is required before their application in routine clinical care. 
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Table 4. Summary of biomarker-based prediction models to assess hepatic fibrosis
Indices Equations
Cut-points for 
advanced  
fibrosis (F3)
Development 
cohort
External  
validation in 
NAFLD
NFS (2007) [96] =−1.675+0.037×age (years)+0.094×BMI (kg/m2)+1.13×IFG/diabetes 
(yes=1, no=0)+0.99×AST/ALT ratio−0.013×platelet (×109/L)−0.66× 
albumin (g/dL)
>0.676, 
<−1.455
NAFLD by  
biopsy  
(Caucasian 
90%)
Yes (validated 
in Korean)
FIB-4 (2006) 
[97]
=age (years)×AST (U/L)/[platelet (109/L)×(ALT [U/L])1/2] >2.67 or 3.25 HIV/HCV by 
biopsy  
(International, 
Caucasian 
77%)
Yes (validated 
in Korean)
ELF test (2008) 
[98,99]
ELF=−7.412+0.681×loge (hyaluronic acid)+0.775×loge (procollagen III N-
terminal peptide)+0.494×loge (tissue inhibitor of metalloproteinase 1)+10
ELF+simple markers panel=−20.870+5.506×ELF 4.513×diabetes⁄IFG−3.14
4×AST⁄ALT−0.058×BMI−0.026×platelet (109/L) 0.639×albumin (g/dL)
≥10.51 NAFLD by bi-
opsy (Cauca-
sian)
Yes (validated 
in viral liver 
diseases,  
Korean)
FibroTest 
(2001) [100] 
Age, sex, total bilirubin, GGT, apolipoprotein A1, haptoglobin, and α2-
macroglobulin
≥0.30 or 0.60 HCV by biopsy 
(France)
Yes (validated 
in viral liver 
diseases,  
Korean)
APRI (2003) 
[101]
=AST (IU/L)/AST upper limit of normal (IU/L)/platelet (109/L) >1.5, <0.5 HCV by biopsy 
(USA)
Yes (validated 
in viral liver 
diseases,  
Korean)
BARD score 
(2008) [102] 
AST/ALT ratio ≥0.8=2 points
BMI ≥28=1 point
Presence of diabetes=1 point
≥2 NAFLD by  
biopsy (USA)
Yes (validated 
in Korean)
Hepascore 
(2005) [103] 
=Y/(1+Y)
Y=exp (−4.185818−0.0249×age+0.7464×sex+1.0039×α2-macroglobulin+ 
0.0302×hyaluronic acid+0.0691×bilirubin−0.0012×GGT)
≥0.5 HCV by biopsy 
(Australia)
No
FibroMeter 
NAFLD 
(2009) [104]
=0.4184×FPG (mmol/L)+0.0701×AST (UI/L)+0.0008×ferritin (μg/L)− 
0.0102×platelet (G/L)−0.0260×ALT (UI/L)+0.0459×body weight (kg)+ 
0.0842×age (year)+11.6226
>0.490:  
significant  
fibrosis (F2)
NAFLD by  
biopsy 
(France) 
No
NAFLD, nonalcoholic fatty liver disease; NFS, NAFLD fibrosis score; BMI, body mass index; IFG, impaired fasting glucose; AST, aspartate ami-
notransferase; ALT, alanine aminotransferase; FIB-4, fibrosis-4; HIV, human immunodeficiency virus; HCV, hepatitis C virus; ELF, Enhanced 
Liver Fibrosis; GGT, γ-glutamyltransferase; APRI, AST to platelet ratio index; FPG, fasting plasma glucose.
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